Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00733031 · ClinicalTrials.gov registry record · Phase 1
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT00733031 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 75 participants.
The verdict
NCT00733031, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD6918 based on the side effects experienced by patients with advanced solid malignancies that receive daily AZD6918 alone. It is possible that AZD6918 will be administered twice daily. Then maximum tolerated doses in combination with either gemcitabine or pemetrexed will also be investigated.
Interventions
- DRUG pemetrexed
- DRUG gemcitabine
- DRUG AZD6918
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00733031
The ClinicalTrials.gov registry entry for NCT00733031 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which pemetrexed is the first listed.
NCT00733031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00733031 about?
NCT00733031 is a clinical study titled "Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918". The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD6918 based on the side effects experienced by patients with advanced solid malignancies that receive daily AZD6918 alone. It is possible that AZD6918 will be administered twice dail...
What is the current status of trial NCT00733031?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2008-08. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00733031?
The interventions under investigation include: pemetrexed (DRUG), gemcitabine (DRUG), AZD6918 (DRUG).
Who is sponsoring clinical trial NCT00733031?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.